Skip to main content
OpenTrials
Completed

NCT Number: NCT01630044

Neurostimulation Device for Treatment of Migraine Headache

This is a single-site, prospective, non-randomized and open label study to investigate the feasibility of home-use CVS for the prevention of episodic migraine headache and specifically to better understand what type of waveform to apply.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke Medicine / Neurology

Durham, North Carolina, 27705, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A history of at least four, and not more than fourteen total monthly headache days of which between four and nine were migraine headache days. (Note: Patients were permitted continued access to migraine abortive medications and were being treated at the Duke University headache clinic.)
  • A history of some responsiveness (incomplete) to at least one and a maximum of two prophylactic pharmaceutical therapies (utilized concurrently);
  • The investigator must have confidence in the patient's ability to reliably complete and return the Daily Headache Diary.
  • Subject must be at least 18 years of age.

Exclusion criteria

  • Individuals who were pregnant, who had a history of cardiovascular disease, who worked night shifts or who had vestibular migraine, menstrual migraine, post-traumatic migraine, a history of unstable mood disorder or unstable anxiety, moderate or greater hearing loss or a history of traumatic brain injury.
  • A history within the last six months of tobacco use, narcotic or barbiturates use or experiencing one or more analgesic rebound headaches.

Treatment and study plan

TNM device

Device

Non-invasive neurostimulator, home-use treatment for up to 43 days.

Primary outcomes

  1. Number of migraine headache days

    Time frame: Length of the study, about 71 days

    Daily Headache Diary will be used by subject. A headache day is defined as a twenty-four hour period which the subject has a headache.

  2. Severity of each and of all headaches

    Time frame: Length of study, 71 days

    Daily Headache Diary will be used by subject. Subject will assign the level of pain based on an eleven-point pain measurement scale from zero (no pain) to ten (most intense pain).

Secondary outcomes

  1. Total Monthly Headache Pain Score

    Time frame: Length of study, about 71 days

    The monthly measure would be the cumulative maximal headache pain scores for all headache days (days on which the subject's head pain level is one or higher on the pain measurement scale) during the month.

Sponsors and collaborators

Lead sponsor

Scion NeuroStim

Industry

Registry information

Official study title

Clinical Pilot Study to Evaluate a Non-Invasive, Neurostimulation Device for Treatment of Migraine Headache

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Jun 28, 2012
Registry last updated
Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.